MB-104

N/A

Report date: 2025/02/08 20:00:06

Base Information

Drug NameMB-104
Drug Alias NameAutologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-cells (Mustang Bio)Autologous Anti-PSCA(dCH2)BBz-CAR T-cells (Mustang Bio)CAR-T cells (Mustang Bio)CS1-CAR T Therapy (Mustang Bio)CS1-CAR T Infusion (Mustang Bio) +[15] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-SLAMF7 +[4] 
TargetsSLAM family member 7Prostate stem cell antigen
Therapy Area/IndicationsUrinary Bladder NeoplasmsProstatic NeoplasmsPancreatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCity Of Hope National Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesMustang Bio IncCity Of Hope National Medical Center
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsProstatic NeoplasmsPancreatic Neoplasms +[5] 
Inactive IndicationsGlioblastoma

Other Information

ATC CodeN/A
Related LinksN/A